Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent
cardiovascular events among myocardial infarction patients. Half of the participants will
receive hydroxychloroquine, whereas the other half will receive placebo during six months.
Phase:
Phase 4
Details
Lead Sponsor:
Helsinki University Central Hospital
Collaborators:
Aarne Koskelo Foundation Finnish Cultural Foundation Finnish Foundation for Cardiovascular Research Orion Corporation, Orion Pharma